NCT04164901 2025-04-03Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)ServierPhase 3 Active not recruiting331 enrolled 25 charts 1 FDA